PMID- 27057096
OWN - NLM
STAT- MEDLINE
DCOM- 20170117
LR  - 20211203
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Print)
IS  - 0962-9351 (Linking)
VI  - 2016
DP  - 2016
TI  - A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human 
      Primary Blood Dendritic Cell Subsets.
PG  - 3605643
LID - 10.1155/2016/3605643 [doi]
LID - 3605643
AB  - Dendritic cells (DCs) are central players of immune responses; they become 
      activated upon infection or inflammation and migrate to lymph nodes, where they 
      can initiate an antigen-specific immune response by activating naive T cells. Two 
      major types of naturally occurring DCs circulate in peripheral blood, namely, 
      myeloid and plasmacytoid DCs (pDCs). Myeloid DCs (mDCs) can be subdivided based 
      on the expression of either CD1c or CD141. These human DC subsets differ in 
      surface marker expression, Toll-like receptor (TLR) repertoire, and 
      transcriptional profile, suggesting functional differences between them. Here, we 
      directly compared the capacity of human blood mDCs and pDCs to activate and 
      polarize CD4(+) T cells. CD141(+) mDCs show an overall more mature phenotype over 
      CD1c(+) mDC and pDCs; they produce less IL-10 and more IL-12 than CD1c(+) mDCs. 
      Despite these differences, all subsets can induce the production of IFN-gamma in 
      naive CD4(+) T cells. CD1c(+) and CD141(+) mDCs especially induce a strong T 
      helper 1 profile. Importantly, naive CD4(+) T cells are not polarized towards 
      regulatory T cells by any subset. These findings further establish all three 
      human blood DCs-despite their differences-as promising candidates for 
      immunostimulatory effectors in cancer immunotherapy.
FAU - Sittig, Simone P
AU  - Sittig SP
AD  - Department of Tumor Immunology, Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences, 6500 HB Nijmegen, Netherlands.
FAU - Bakdash, Ghaith
AU  - Bakdash G
AD  - Department of Tumor Immunology, Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences, 6500 HB Nijmegen, Netherlands.
FAU - Weiden, Jorieke
AU  - Weiden J
AD  - Department of Tumor Immunology, Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences, 6500 HB Nijmegen, Netherlands.
FAU - Skold, Annette E
AU  - Skold AE
AD  - Department of Tumor Immunology, Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences, 6500 HB Nijmegen, Netherlands; Department 
      of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, 171 76 
      Stockholm, Sweden.
FAU - Tel, Jurjen
AU  - Tel J
AD  - Department of Tumor Immunology, Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences, 6500 HB Nijmegen, Netherlands.
FAU - Figdor, Carl G
AU  - Figdor CG
AD  - Department of Tumor Immunology, Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences, 6500 HB Nijmegen, Netherlands.
FAU - de Vries, I Jolanda M
AU  - de Vries IJ
AD  - Department of Tumor Immunology, Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences, 6500 HB Nijmegen, Netherlands; Department 
      of Medical Oncology, Radboud University Medical Center, Radboud Institute for 
      Molecular Life Sciences, 6500 HB Nijmegen, Netherlands.
FAU - Schreibelt, Gerty
AU  - Schreibelt G
AUID- ORCID: 0000-0002-0156-8365
AD  - Department of Tumor Immunology, Radboud University Medical Center, Radboud 
      Institute for Molecular Life Sciences, 6500 HB Nijmegen, Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160207
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
RN  - 0 (Antigens, CD1)
RN  - 0 (Antigens, Surface)
RN  - 0 (CD1C protein, human)
RN  - 0 (Glycoproteins)
RN  - 0 (THBD protein, human)
RN  - 0 (Thrombomodulin)
RN  - 0 (Toll-Like Receptors)
RN  - 130068-27-8 (Interleukin-10)
RN  - 187348-17-0 (Interleukin-12)
SB  - IM
MH  - Antigens, CD1/metabolism
MH  - Antigens, Surface/metabolism
MH  - CD4-Positive T-Lymphocytes/metabolism
MH  - Cells, Cultured
MH  - Dendritic Cells/drug effects/*metabolism
MH  - Glycoproteins/metabolism
MH  - Humans
MH  - Interleukin-10/metabolism
MH  - Interleukin-12/metabolism
MH  - Myeloid Cells/immunology/metabolism
MH  - T-Lymphocytes/drug effects/*metabolism
MH  - Thrombomodulin
MH  - Toll-Like Receptors/metabolism
PMC - PMC4761397
EDAT- 2016/04/09 06:00
MHDA- 2017/01/18 06:00
PMCR- 2016/02/07
CRDT- 2016/04/09 06:00
PHST- 2015/08/31 00:00 [received]
PHST- 2015/12/21 00:00 [revised]
PHST- 2016/01/04 00:00 [accepted]
PHST- 2016/04/09 06:00 [entrez]
PHST- 2016/04/09 06:00 [pubmed]
PHST- 2017/01/18 06:00 [medline]
PHST- 2016/02/07 00:00 [pmc-release]
AID - 10.1155/2016/3605643 [doi]
PST - ppublish
SO  - Mediators Inflamm. 2016;2016:3605643. doi: 10.1155/2016/3605643. Epub 2016 Feb 7.